PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-272.88%
Negative net income growth while TRAW stands at 11.16%. Joel Greenblatt would see a comparative disadvantage in bottom-line performance.
77.92%
Some D&A expansion while TRAW is negative at -1.02%. John Neff would see competitor’s short-term profit advantage unless expansions here deliver big returns.
100.00%
Deferred tax of 100.00% while TRAW is zero at 0.00%. Bruce Berkowitz would see a partial difference that can matter for future cash flow if large in magnitude.
49.65%
SBC growth well above TRAW's 20.79%. Michael Burry would flag major dilution risk vs. competitor’s approach.
56.13%
Slight usage while TRAW is negative at -97.48%. John Neff would note competitor possibly capturing more free cash unless expansions are needed here.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
59.43%
A yoy AP increase while TRAW is negative at -79.25%. John Neff would see competitor possibly improving relationships or liquidity more rapidly.
-0.47%
Negative yoy usage while TRAW is 13.60%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
85.22%
Some yoy increase while TRAW is negative at -200.00%. John Neff would see competitor possibly reining in intangible charges or revaluations more effectively than we do.
-64.88%
Negative yoy CFO while TRAW is 5.90%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
82.30%
CapEx growth well above TRAW's 100.00%. Michael Burry would suspect heavier cash outlays that risk short-term free cash flow vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
82.30%
We have mild expansions while TRAW is negative at -100.00%. John Neff sees competitor possibly divesting or pausing expansions more aggressively.
-39.13%
We cut debt repayment yoy while TRAW is 0.00%. Joel Greenblatt sees competitor possibly lowering risk more if expansions do not hamper them.
-90.34%
Negative yoy issuance while TRAW is 0.00%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.